Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...

Adaptive Mechanisms in Cancer Cells

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...

Biosynthesis of Nucleic Acids

Biosynthesis of Nucleic Acids

Nucleic acid biosynthesis is a fundamental biochemical process that produces the purine and pyrimidine nucleotides essential for DNA and RNA synthesis. This pathway maintains a balanced nucleotide pool, preventing imbalances that could jeopardize genetic integrity and cellular function. Given the crucial role of nucleotides, their synthesis is tightly regulated to ensure proper cellular homeostasis.Purine BiosynthesisThe biosynthesis of purine nucleotides begins with ribose-5-phosphate, a...

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Ketogenic diet mediates intestinal tumorigenesis through lipids not ketones.

Nature·2026

Same author

Randomized comparison of lipid-containing and non-lipid-containing artificial tears on tear film dynamics over a 3-month period.

Optometry and vision science : official publication of the American Academy of Optometry·2026

Same author

Local signals, systemic decline.

Science (New York, N.Y.)·2026

Same author

Epigenetic and oncogenic inhibitors converge to drive a metabolic catastrophe in castration-resistant prostate cancer.

The Journal of clinical investigation·2026

Same author

The Influence of Diet on Cancer Progression and Treatment.

Annual review of nutrition·2026

Same author

Aconitase 2 the rescue: A safeguard against excess mitochondrial citrate.

Molecular cell·2026

Search research articles

Related Experiment Video

Updated: Sep 29, 2025

Evaluation of Amino Acid Consumption in Cultured Bone Cells and Isolated Bone Shafts

Evaluation of Amino Acid Consumption in Cultured Bone Cells and Isolated Bone Shafts

Published on: April 13, 2022

Inhibiting GLUTtony in cancer.

Sarah M Chang¹, Matthew G Vander Heiden²

¹Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA; Department of Biology, Massachusetts Institute of Technology, Cambridge, MA, USA.

Cell Chemical Biology

|March 18, 2022

Summary

Researchers developed a novel small molecule inhibitor to block glucose uptake in cancer cells, suppressing tumor growth. They also discovered how cancer cells adapt to reduced glucose availability.

More Related Videos

Spectrophotometric Screening for Potential Inhibitors of Cytosolic Glutathione S-Transferases

Spectrophotometric Screening for Potential Inhibitors of Cytosolic Glutathione S-Transferases

Published on: October 10, 2020

Determining the Optimal Inhibitory Frequency for Cancerous Cells Using Tumor Treating Fields TTFields

Determining the Optimal Inhibitory Frequency for Cancerous Cells Using Tumor Treating Fields TTFields

Published on: May 4, 2017

Related Experiment Videos

Last Updated: Sep 29, 2025

Evaluation of Amino Acid Consumption in Cultured Bone Cells and Isolated Bone Shafts

Evaluation of Amino Acid Consumption in Cultured Bone Cells and Isolated Bone Shafts

Published on: April 13, 2022

Spectrophotometric Screening for Potential Inhibitors of Cytosolic Glutathione S-Transferases

Spectrophotometric Screening for Potential Inhibitors of Cytosolic Glutathione S-Transferases

Published on: October 10, 2020

Determining the Optimal Inhibitory Frequency for Cancerous Cells Using Tumor Treating Fields TTFields

Determining the Optimal Inhibitory Frequency for Cancerous Cells Using Tumor Treating Fields TTFields

Published on: May 4, 2017

Area of Science:

Biochemistry
Cancer Biology
Drug Discovery

Background:

Cancer cells exhibit increased glucose uptake.
Targeting glucose transporters (GLUTs) is a potential anti-cancer strategy.
Developing effective GLUT inhibitors remains a challenge.

Purpose of the Study:

To develop and characterize novel small molecules that inhibit glucose uptake in cancer.
To investigate the therapeutic potential of a pan-GLUT inhibitor in suppressing tumor growth.
To understand the adaptive mechanisms of cancer cells to glucose restriction.

Main Methods:

Chemical synthesis and characterization of novel small molecules.
In vitro assays to assess glucose uptake inhibition.
In vivo studies using tumor models to evaluate efficacy.
Analysis of cancer cell metabolism and adaptive responses.

Main Results:

Identification and characterization of a novel pan-GLUT inhibitor.
Demonstration that the inhibitor suppresses tumor growth.
Uncovering specific mechanisms by which cancer cells adapt to glucose restriction.
The inhibitor effectively reduces glucose uptake in cancer cells.

Conclusions:

Novel small molecules can effectively inhibit glucose uptake in cancer.
Pan-GLUT inhibitors show promise for cancer therapy.
Understanding cancer cell adaptation is crucial for overcoming therapeutic resistance.